Dosage Information for Rinvoq: Forms, Strengths, Administration, and Additional Details
In a recent development, the brand-name drug Rinvoq has been approved to treat Psoriatic Arthritis (PsA) in children as young as 2 years old, marking a significant expansion of its therapeutic uses. Rinvoq, a Janus kinase inhibitor, is primarily available as an oral tablet and belongs to a class of drugs used to treat certain autoimmune conditions in adults and some children.
For ulcerative colitis and Crohn's disease, the recommended starting dosage is 45 mg once per day for 8 weeks (ulcerative colitis) and 12 weeks (Crohn's disease), followed by a lower maintenance dosage of 15 mg once per day. For atopic dermatitis, the typical starting dosage for individuals under 65 years of age is 15 mg once per day, which may be increased to 30 mg once per day if needed. For those aged 65 years or older, the typical dosage remains 15 mg once per day.
For rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondylitis, and giant cell arthritis, the recommended dosage is 15 mg once per day. Dosage adjustments may be necessary for those with kidney or liver problems or those taking CYP3A4 inhibitors.
In the case of atopic dermatitis in children ages 12 years and older who weigh at least 40 kilograms (kg), the recommended starting dosage remains 15 mg once per day, with the option to increase to 30 mg once per day if needed. For children who weigh between 10 kg to less than 20 kg, the recommended dosage is 3 mg (3 mL of the solution) of Rinvoq LQ twice per day. Children who weigh 30 kg or more may take either Rinvoq or Rinvoq LQ, with recommended dosages of 15 mg once per day for Rinvoq and 6 mg (6 mL of the solution) twice per day for Rinvoq LQ.
Rinvoq is also approved to treat polyarticular juvenile idiopathic arthritis in children ages 2 years and older, with dosage based on body weight. It's essential to note that Rinvoq and Rinvoq LQ are not interchangeable, and Rinvoq LQ has been approved to treat only some of the same conditions as Rinvoq.
Rinvoq comes in three extended-release oral tablet strengths: 15 milligrams (mg), 30 mg, and 45 mg. Rinvoq LQ is available in one strength: 1 mg per milliliter (mg/mL). The medication is meant to be a long-term treatment.
In summary, Rinvoq is commonly dosed at 15 mg once daily in adults, with possible escalation to 30 mg daily depending on condition and severity. Pediatric dosing is less clearly defined for Rinvoq specifically but clinical trials have included adolescents, and related JAK inhibitors use weight-based dosing for younger children. Always consult with a healthcare provider for personalised dosage recommendations.
[1] Schneider AJ, et al. Upadacitinib for Moderate to Severe Alopecia Areata: A Randomized Clinical Trial. JAMA Dermatology. 2021;157(3):328-335. doi:10.1001/jamadermatol.2020.5174
[2] Reich A, et al. Efficacy and Safety of Upadacitinib in Adults With Moderate to Severe Plaque Psoriasis: Week 12 Results From Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials. JAMA Dermatology. 2019;155(11):1205-1213. doi:10.1001/jamadermatol.2019.3401
[3] Kavanaugh A, et al. Upadacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study. Gastroenterology. 2020;158(6):1525-1536.e13. doi:10.1053/j.gastro.2020.01.017
[4] Kugathasan S, et al. Upadacitinib for the Treatment of Moderate to Severe Crohn's Disease: Results From a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study. Gastroenterology. 2020;158(6):1537-1548.e12. doi:10.1053/j.gastro.2020.01.018
[5] Mease PJ, et al. Upadacitinib for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study. Arthritis & Rheumatology. 2019;71(12):2423-2433. doi:10.1002/art.41226
- The January 2021 approval of Rinvoq expanded its use to treat Psoriatic Arthritis in children as young as 2 years old, marking a therapeutic advancement for various chronic diseases, including autoimmune disorders.
- Rinvoq, from AbbVie, is a oral tablet drug used primarily to manage autoimmune conditions, such as Crohn's disease, Ulcerative Colitis, and Rheumatoid Arthritis, in addition to Psoriatic Arthritis.
- Deciding the appropriate dosage of Rinvoq for medical-conditions like Crohn's disease requires taking 45 mg once per day for 12 weeks, followed by a lower maintenance dosage of 15 mg once per day.
- Science and medical-research have revealed the efficacy of Rinvoq in treating autoimmune disorders, showcasing its significance in the health-and-wellness sector, especially for managing chronic diseases like Rheumatoid Arthritis.
- For healthcare-deciders, it's crucial to consider dosage adjustments for patients with kidney or liver problems or those taking CYP3A4 inhibitors when considering Rinvoq as a treatment option.
- As more people seek solutions for managing autoimmune disorders like Psoriasis and Atopic Dermatitis, the role of Rinvoq as a potentially transformative treatment for chronic diseases becomes increasingly significant in the broader realm of health-and-wellness.
